ArticleOncotarget2017
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Telomerase activation in the treatment of aging or degenerative diseases: a systematic review.Molecular and cellular biochemistry · 2021Pooled it
- Biogenesis and Regulation of Telomerase during Development and Cancer.Cold Spring Harbor perspectives in biology · 2026Review
- Incorporation of network pharmacology, molecular docking, survival, density functional theory, and experimental studies to explore the potential key targets of formononetin by TERT-mediated anti-cancer effects in MCF-7 breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploratory analysis of gene aberrations and chemotherapy response: findings from a real-world database in Japan.British journal of cancer · 2026Observational
- Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.British journal of cancer · 2024Article
- The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients.Scientific reports · 2024Article
- The expression ofFrontiers in endocrinology · 2024Article
- Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle.Advances in experimental medicine and biology · 2024Review
- Mechanisms of Breast Cancer Stem Cell Specification and Self-Renewal Mediated by Hypoxia-Inducible Factor 1.Stem cells translational medicine · 2023Article
- Copy-number-gain of telomerase reverse transcriptase (hTERT) is associated with an unfavorable prognosis in esophageal adenocarcinoma.Scientific reports · 2023Article
- Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations.Frontiers in cell and developmental biology · 2023Review
- Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.Diagnostic pathology · 2022Article
- THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.Clinical epigenetics · 2022Article
- Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers.Cancers · 2022Article
- Differential DNA Methylation of THOR andCancers · 2022Article
- TAaCGH Suite for Detecting Cancer-Specific Copy Number Changes Using Topological Signatures.Entropy (Basel, Switzerland) · 2022Article
- Relationship between Telomere Length,International journal of molecular sciences · 2022Article
- Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.Frontiers in oncology · 2022Article
- Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.The Journal of clinical investigation · 2021Article
- Decoding human cancer with whole genome sequencing: a review of PCAWG Project studies published in February 2020.Cancer metastasis reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upregulation of the telomerase reverse transcriptase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.